Christoph Esslinger

Cerecin, Inc. develops therapies to treat central nervous system disorders. It offers therapeutic treatments for Parkinson's disease, Alzheimer's disease, and other age-related memory loss disorders. The firm is also developing therapies that address metabolic deficiencies and provide an alternative energy source for brain cells. The company was founded in 2001 and is headquartered in Boulder, CO.

IsoTis, Inc. designs, manufactures and sells bone graft substitutes and other devices. The company was founded on November 15, 2006 and is headquartered in Plainsboro, NJ.

Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland.

Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY.

Inventages Venture Capital Investment, Inc (Inventages Venture) is a venture capital firm founded in 2000 by Gunnar Carsten Weikert. The firm is headquartered in Nassau with an additional office in London.

SelectX Pharmaceuticals, Inc. engages in the discovery and development of aminoglycoside therapeutics for unmet medical needs. Its advanced program, development candidate SXP2523, is a next generation aminoglycoside antibiotic for drug resistant gram-negative hospital-acquired infections (HAIs); SXP2523 possesses broad spectrum coverage with potency against Pseudomonas, Klebsiella, Acinetobacter, E. coli, and Staphylococcus. The company was founded by Michael G. Chaparian and Charles R. Cantor in 2002 and is headquartered in Boston, MA.

Philip Morris USA, Inc. makes and markets tobacco goods. Its products include cigarette non-tobacco, cigarette tobacco and flavor ingredients. The company was founded by Philip Morris in 1847 and is headquartered in Richmond, VA.

AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands.

Redalpine Venture Parners AG (Redalpine) is an independent venture capital investment firm headquartered in Zurich, Switzerland. The firm was founded in 2006.

BioMedPartners AG (BMP), is an independant venture capital firm headquartered in Basel, Switzerland. BMP originated in 2002 as Seed Capital Advisors AG. The firm manages sector-focused venture capital funds including BioMedInvest, BioMedInvest II and BioMedCredit. They specialize in the biomedical sector.

ImmunoBiology Ltd. develops next generation of vaccines for infectious diseases. It develops vaccines that protect against pathogens by mimicking the natural immune response to infection. The firm offers ImmBioVax and ImmunoBodies vaccines. The company was founded by Camilo Colaco in 1999 and is headquartered in Cambridge, the United Kingdom.

Novosom Verwaltungs GmbH provides clinical development services and hospital equipment. It offers its own euqipment and technology to discover new methods of healing and researching on ribonucleic acid. The company was founded by Steffen Panzner in 1999 and is headquartered in Halle, Germany.

Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland.

AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands.

Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland.

Humedics GmbH operates as a research-based medtech company. It focuses on rapid and precise lover function measurement using LiMax, a breath analysis technology. The company was founded by Martin Stockman, Erwin de Bujizer, and Karsten Heyne in 2009 and is headquartered in Berlin, Germany.

HeatMatrix Group BV develops and manufactures plastic heat exchangers for waste heat recovery from industrial corrosive flue gas. The firm’s heat exchangers can be used in the petrochemicals and chemicals, bio-energy, food, agricultural, and paper industries. Its products include air pre-heater, hybrid exchanger, gas to liquid, and in situ cleaning system. The company was founded by Erik van den Berg in 2008 and is headquartered in Geldermalsen, the Netherlands.

LNC Therapeutics SA operates as a research and development company that designs and develops medical food formulas. It's develop therapeutic solutions for metabolic and cardiometabolic disorders. The firm also designs and develops formulas for obesity and pre-diabetes sickness. Its products include Stablor, Bariamed, and Fertimed. It encompass serious game, patient community, and support tools: BariaSpoon and BariaFork. The company was founded by Jérôme Théron and Claude Vincent on October 29, 2010 and is headquartered in Bordeaux, France.

AYOXXA Biosystems GmbH operates as a biotechnology firm. Its lunaris technology is the optimal analysis platform for the pre-clinical and clinical development work. The firm offers In-situ encoded bead array, a multiplexed protein analysis platform that allows users to measure proteins and biomolecular analytes. The company was founded by Dieter Trau and Andreas Schmidt in 2010 and is headquartered in Cologne, Germany.

Ventaleon GmbH is a biotechnology company, which engages in the development of inhaled treatments against viral infections. Its products include LASAG (D,L-lysine acetylsalicylate • glycine), a lysin-salt formulation of well known acetyl salicylic acid. The company was founded by Gerhard Scheuch in 2012 and is headquartered in Gauting, Germany.

Medimaps Group SA designs and provides medical tools. The company is headquartered in Plan-les-Ouates, Switzerland.

Step Pharma SAS develops drugs for immunosuppressive therapies. The company was founded by Geoffroy de Ribains, Alain Fischer, and Sylvain Latour and is headquartered in Paris, France.

HepaRegeniX GmbH engages in the development of treatment for acute and chronic liver diseases. It focuses on Mitogen-Activated Protein Kinase 4, which unlocks the regenerative capacity of hepatocytes even in severely diseased livers. The company was founded in by Wolfgang Albrecht in 2017 and is headquartered in Tuebingen, Germany.

Genialis, Inc. develops software for biologists in solving complex analyses. The software helps in automation of data and analyzing task for exploring and sharing the results. The company is headquartered in Houston, TX.

Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland.

Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff.

Araris Biotech AG engages in the development and research of an antibody-drug conjugate (ADC) linker technology. It focuses on the production of ADCs. Its linker platform enables the attachment of payload to off the shelf antibodies without the need of antibody engineering. The company was founded by Philipp Spycher, Isabella Attinger-Toller, and Dragan Grabulovski and is headquartered in Z?rich, Switzerland.

Mushlabs GmbH is a technology-driven company, which produces food from edible mushroom mycelia. The company was founded by Mazen Rizk and is headquartered in Berlin, Germany.

Better Dairy Ltd. operates in the dairy industry. The British company was founded in 2020 by Jevan Nivasa Nagarajah and Christopher Robert Reynolds. Jevan Nivasa Nagarajah has been the CEO since 2020.

Tribune Therapeutics AB is a preclinical biopharmaceutical company that focuses on developing novel medicines to treat patients with fibrotic diseases. Healthcap and Novo Seeds provided funding for the company, and they are based in Stockholm, Sweden. The Swedish company was created by Healthcap and Novo Seeds, the early-stage investment and company creation team of Novo Holdings. The company was founded in 2020 and has in-licensed an asset from one of the largest technology transfer offices in the Nordic region. The founders of the company are Håvard Attramadal, Ole J. Kaasbøll, and Georg Vo Beiske, who has been the CEO since 2020.

WF World Fund Management GmbH (WF World Fund Management) is a venture capital firm founded in 2021. The firm is headquartered in Berlin, Germany.

Luya Foods AG is a Swiss company that specializes in producing vegan meat substitutes. Luya Foods is based in Zollikofen, Switzerland. The company's products are known for being tender, juicy, and flavorful. The company prides itself on being 100%% Swiss made and 100%% vegan.

Lead Pharma Holding BV develops small-molecule drugs for the treatment of autoimmune diseases and cancer. It specializes in medicinal, computational, and protein chemistry, x-ray crystallography, cell biology, and integration x-omics. The company was founded by Ad van Gorp, Leon de Windt, and Pieter Doevendans in 2007 and is headquartered in Oss , the Netherlands.